CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
可能影响急性髓系白血病未来管理的新型研究性药物和通路
英文原题：Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia.
查看英文原题
Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
急性髓系白血病（AML）是一种临床异质性很高的疾病，2012至2018年间5年总生存率为32%。随着年龄增长及疾病风险升高，该数值会大幅下降，因此新药研发机会迫切，也是当前亟需解决的未满足需求。全球基础科学和临床研究人员正通过研究新旧分子制剂及联合策略，努力改善AML治疗结局。本文综述处于不同临床开发阶段、用于AML患者的部分有前景新药。
展开英文摘要原文
Acute Myeloid leukemia (AML) is a clinically heterogeneous disease with a 5-year overall survival of 32% between 2012 to 2018. The above number severely dwindles with age and adverse risk of disease, presenting opportunities for new drug development and is an area of dire unmet need.
Basic science and clinical investigators across the world have been working on many new and old molecule formulations and combination strategies to improve outcomes in this disease. In this review, we discuss select promising novel agents in various stages of clinical development for patients with AML.
论文信息
- 作者
- Premnath N、Madanat YF
- 单位
- Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.United States
- 文献类型
- 综述
- 期刊
- Cancers2023 May 29
- 原文标识
- PubMed 37296920 · DOI 10.3390/cancers15112958
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →